Helicore Debuts With $65m, Plans For GIP Antagonism In Obesity

 
• By Joseph Haas

Backed by Versant Ventures, Helicore will pursue optimized therapy for underserved obesity patients with an antibody that directly antagonizes GIP and plans for antibody conjugate therapies.

Versant Ventures backs Helicore to compete in the already busy obesity arena (Shutterstock)

More from Financing

More from Therapy Areas